ONE-BRIDGE: Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome
Study Details
Study Description
Brief Summary
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The objectives of this clinical study are as follows(ARDS caused by pneumonia cohort):
-
Primary objective To investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonia
-
Secondary objective To confirm the safety of HLCM05 in patients with ARDS caused by pneumonia
-
Exploratory objective To investigate changes of biomarkers in patients with ARDS caused by pneumonia
The number of patients enrolled is 30 (20 patient in the HLCM051 group and 10 patients in the standard therapy group)
The objectives of this clinical study is as follows(ARDS caused by COVID-19 cohort):
- Exploratory objective To investigate the safety and the efficacy of HLCM051 in patients with ARDS caused by SARS-Cov-2 infection
The number of patients enrolled is Approximately 5 (the HLCM051 group only)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HLCM051 group【ARDS caused by pneumonia cohort】 Patients will receive the standard therapy A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute |
Biological: HLCM051
HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
|
| No Intervention: Standard treatment group【ARDS caused by pneumonia cohort】 •Patients will receive the standard therapy |
|
| Experimental: HLCM051 group【ARDS caused by COVID-19 cohort 】 Patients will receive the standard therapy A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute |
Biological: HLCM051
HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
|
Outcome Measures
Primary Outcome Measures
- Ventilator-free days (VFD)(ARDS caused by pneumonia cohort) [28 days after administration of the investigational product]
VFD for 28 days after administration of the investigational product
- Adverse events(ARDS caused by COVID-19 cohort) [From informed consent to 180 days after administration of the investigational product]
The number and rate of adverse events
- Change from baseline in systolic blood pressure(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in systolic blood pressure(mmHg)
- Change from baseline in diastolic blood pressure(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in diastolic blood pressure(mmHg)
- Change from baseline in pulse rate(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in pulse rate(beats/min)
- Change from baseline in respiration(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in respiration(breath/min)
- Change from baseline in oxygen saturation(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in oxygen saturation(%)
- Change from baseline in body temperature(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in body temperature(C)
- Change from baseline in red blood cell count(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in red blood cell count(/uL)
- Change from baseline in hemoglobin(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in hemoglobin(g/dL)
- Change from baseline in hematocrit(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in hematocrit(%)
- Change from baseline in leukocyte count(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in leukocyte count(/uL)
- Change from baseline in neutrophils(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in neutrophils(%)
- Change from baseline in eosinophils(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in eosinophils(%)
- Change from baseline in basophils(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in basophils(%)
- Change from baseline in lymphocytes(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in lymphocytes(%)
- Change from baseline in monocytes(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in monocytes(%)
- Change from baseline in platelet count(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in platelet count(/uL)
- Change from baseline in asparate aminotransferase(AST)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in asparate aminotransferase(AST)(IU/L)
- Change from baseline in alanine aminotransferase(ALT)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in alanine aminotransferase(ALT)(IU/L)
- Change from baseline in alkaline phosphatase(ALP)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in alkaline phosphatase(ALP)(IU/L)
- Change from baseline in total bilirubin(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in total bilirubin(mg/dL)
- Change from baseline in blood urea nitrogen(BUN)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in blood urea nitrogen(BUN)(mg/dL)
- Change from baseline in creatinine(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in creatinine(mg/dL)
- Change from baseline in sodium(Na)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in sodium(Na)(mmol/L)
- Change from baseline in potassium(K)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in potassium(K)(mmol/L)
- Change from baseline in chloride(Cl)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in chloride(Cl)(mmol/L)
- Change from baseline in calcium(Ca)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in calcium(Ca)(mg/dL)
- Change from baseline in blood sugar(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in blood sugar(mg/dL)
- Change from baseline in urinary protein(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in urinary protein(- to >= 4+)
- Change from baseline in urinary sugar(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in urinary sugar(- to >= 4+)
- Change from baseline in uric blood(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in uric blood(- to >= 4+)
- Change from baseline in urinary sediment(RBC)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in urinary sediment(RBC)(/HPF)
- Change from baseline in urinary sediment(WBC)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in urinary sediment(WBC)(/HPF)
- Change from baseline in urinary sediment(Other)(ARDS caused by COVID-19 cohort) [From screening to 180 days after administration of the investigational product]
Change from baseline in urinary sediment(Other)(/HPF)
Eligibility Criteria
Criteria
Inclusion Criteria(ARDS caused by pneumonia cohort):
-
Provision of informed consent by the patient or his/her legal representative in case the patient is incapable of giving consent due to sedation etc
-
Male or female aged 20 to 90 years at informed consent (Asians only)
-
Patients with ARDS caused by pneumonia of those who were diagnosed as having ARDS according to the Berlin Definition
-
Patients who are confirmed to have the following findings in the Berlin Definition within the same 24 hours 1)PaO2/FiO2 (P/F) ratio ≤ 300 mmHg with positive end-expiratory pressure (PEEP) ≥ 5 cmH2O 2)Bilateral opacities on chest X-ray or CT (not fully explained by effusions, lobar/lung collapse, and nodular shadow) 3)Respiratory failure that cannot be explained by cardiac failure and fluid overload
-
Patients who underwent chest high-resolution computed tomography (HRCT)
-
Patients with HRCT score ≥211 according to the abbreviated HRCT scoring system
-
Patients with APACHE II score <27 at the diagnosis of ARDS
-
Patients who underwent artificial respiration with intubation
-
Patients who can start receiving the investigational product within 72 hours (3 days) after the diagnosis of ARDS
-
Patients whose condition is expected to be stable for at least 4 hours after initiating investigational product administration "Stable" means the condition where there is no need for significant sustained increase in FiO2 or PEEP and the supportive care for the cardiovascular system is not required (e.g. an increase in the dose of norepinephrine or epinephrine by ≥0.1 mcg/kg/min or an increase in the dose of inotropic agent or vasopressor by ≥20% besides norepinephrine and epinephrine for blood pressure control)
-
Women who are neither pregnant, breastfeeding, planning to become pregnant during the study period. Women of childbearing potential must agree on the use of appropriate contraceptive methods under the guidance of investigators through the completion of the clinical study
-
Male patients who have female partners of childbearing potential must agree on the use of appropriate contraceptive methods under the guidance of investigators through the completion of the clinical study
Exclusion Criteria(ARDS caused by pneumonia cohort):
-
Patients without life expectancy of 48 hours
-
Patients who are under artificial dialysis at screening
-
Patients whose life expectancy is <6 months because of complications at screening
-
Patients under ventilator at home due to chronic respiratory disease
-
Patients who have been on mechanical ventilation for ≥ 1 week
-
Patients with obvious honeycomb lung at screening consistent with pre-existing late-stage interstitial lung disease
-
Patients with clinically evident findings consistent with diffuse alveolar hemorrhage
-
Patients with chronic respiratory disease that requires continuous domiciliary oxygen therapy
-
Patients with severe COPD (stage III or severe according to the GOLD Classification)
-
Patients with chronic pulmonary hypertension (class III or IV according to the World Health Organization Classification of Functional Status of Patients With Pulmonary Hypertension)
-
Patients with a history of lung lobectomy, single-lung pneumonectomy or pulmonary transplantation
-
Patients who are appropriate to be treated with extracorporeal membrane oxygenation (ECMO) at screening
-
Patients who were resuscitated after cardio-respiratory arrest
-
Patients with a history of ST-segment elevation myocardial infarction within 6 months before informed consent
-
Patients with mean arterial (blood) pressure (MAP) <60 mmHg despite treatment with one or more vasopressor or cardiotonic agent
-
Patients with severe chronic liver disease (Child-Pugh >10)
-
Patients with a history of transplantation with autologous or allogeneic, bone marrow or peripheral stem cells for other purposes than the treatment of hematological tumor
-
Patients with malignancy requiring treatment at screening
-
Patients infected with human immunodeficiency virus (HIV)
-
Patients with a history of acute allergic reaction to the preparations derived from human tissues, bovine or swine materials, and those who refuse the use of biological products due to religious reasons
-
Patients for whom ARDS is not judged as the chief complaint by the investigator (sub-investigator) based on clinical findings
-
Patients who received other investigational drugs or products within 30 days prior to informed consent
-
Patients who are participating or planned to participate in other clinical studies (except for observational clinical researches that do not require intervention) during this clinical study
-
Patients who are inappropriate to participate in this clinical study because of significant complications (such as pneumothorax ) or psychiatric disorders as judged by the investigator
-
Patients who is suspected SARS-CoV-2 infection
Inclusion Criteria(ARDS caused by COVID-19 cohort ):
-
Provision of informed consent by the patient or his/her legal representative in case the patient is incapable of giving consent due to sedation etc.
-
Male or female aged 20 to 70 years at informed consent (Asians only)
-
Patients tested positive for COVID-19
-
Patients with ARDS caused by COVID-19 of those who were diagnosed as having ARDS according to the Berlin Definition
-
Patients who are confirmed to have the following findings in the Berlin Definition within the same 24 hours 1)PaO2/FiO2 (P/F) ratio ≤ 300 mmHg with positive end-expiratory pressure (PEEP) ≥ 5 cmH2O 2)Bilateral opacities on chest X-ray or CT (not fully explained by effusions, lobar/lung collapse, and nodular shadow) 3)Respiratory failure that cannot be explained by cardiac failure and fluid overload
-
Patients who underwent Chest X-ray, chest CT or high-resolution computed tomography (HRCT) as far as possible
-
Patients with APACHE II score <27 at the diagnosis of ARDS
-
Patients who underwent artificial respiration with intubation
-
Patients who can start receiving the investigational product within 72 hours (3 days) after the diagnosis of ARDS
-
Women who are neither pregnant, breastfeeding, planning to become pregnant during the study period. Women of childbearing potential must agree on the use of appropriate contraceptive methods under the guidance of investigators through the completion of the clinical study
-
Male patients who have female partners of childbearing potential must agree on the use of appropriate contraceptive methods under the guidance of investigators through the completion of the clinical study
Exclusion Criteria(ARDS caused by COVID-19 cohort ):
-
Patients without life expectancy of 48 hours
-
Patients who are under artificial dialysis at screening
-
Patients whose life expectancy is <6 months because of complications at screening
-
Patients under ventilator at home due to chronic respiratory disease
-
Patients who have been on mechanical ventilation for ≥ 1 week
-
Patients with obvious honeycomb lung at screening consistent with pre-existing late-stage interstitial lung disease
-
Patients with clinically evident findings consistent with diffuse alveolar hemorrhage
-
Patients with chronic respiratory disease that requires continuous domiciliary oxygen therapy
-
Patients with severe COPD (stage III or severe according to the GOLD Classification)
-
Patients with chronic pulmonary hypertension (class III or IV according to the World Health Organization Classification of Functional Status of Patients With Pulmonary Hypertension)
-
Patients with a history of lung lobectomy, single-lung pneumonectomy or pulmonary transplantation
-
Patients who are appropriate to be treated with extracorporeal membrane oxygenation (ECMO) at screening
-
Patients who were resuscitated after cardio-respiratory arrest
-
Patients with a history of ST-segment elevation myocardial infarction within 6 months before informed consent
-
Patients with mean arterial (blood) pressure (MAP) <60 mmHg despite treatment with one or more vasopressor or cardiotonic agent
-
Patients with severe chronic liver disease (Child-Pugh >10)
-
Patients with a history of transplantation with autologous or allogeneic, bone marrow or peripheral stem cells for other purposes than the treatment of hematological tumor
-
Patients with malignancy requiring treatment at screening
-
Patients infected with human immunodeficiency virus (HIV)
-
Patients with a history of acute allergic reaction to the preparations derived from human tissues, bovine or swine materials, and those who refuse the use of biological products due to religious reasons
-
Patients for whom ARDS is not judged as the chief complaint by the investigator (sub-investigator) based on clinical findings
-
Patients who have used other investigational drugs or products within 30 days before informed consent (excluding other investigational drugs or products used for the purpose of treating COVID-19)
-
Patients who are participating or planning to participate in other clinical studies during the study period (excluding other clinical studies, clinical researches and observational clinical researches that do not require intervention for the purpose of treating COVID-19)
-
Patients who are inappropriate to participate in this clinical study because of significant complications (such as pneumothorax ) or psychiatric disorders as judged by the investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Investigational Site Number 027 | Nagoya | Aichi | Japan | |
| 2 | Investigational Site Number 028 | Nagoya | Aichi | Japan | |
| 3 | Investigational Site Number 005 | Seto | Aichi | Japan | |
| 4 | Investigational Site Number 020 | Toyoake | Aichi | Japan | |
| 5 | Investigational Site Number 003 | Hirosaki | Aomori | Japan | |
| 6 | Investigational Site Number 007 | Iizuka | Fukuoka | Japan | |
| 7 | Investigational Site Number 019 | Ōgaki | Gifu | Japan | |
| 8 | Investigational Site Number 011 | Sapporo | Hokkaido | Japan | |
| 9 | Investigational Site Number 010 | Kobe | Hyogo | Japan | |
| 10 | Investigational Site Number 013 | Kobe | Hyogo | Japan | |
| 11 | Investigational Site Number 017 | Takarazuka | Hyogo | Japan | |
| 12 | Investigational Site Number 025 | Yokohama | Kanagawa | Japan | |
| 13 | Investigational Site Number 029 | Yokohama | Kanagawa | Japan | |
| 14 | Investigational Site Number 018 | Kashihara | Nara | Japan | |
| 15 | Investigational Site Number 026 | Suita | Osaka | Japan | |
| 16 | Investigational Site Number 022 | Ōtsu | Shiga | Japan | |
| 17 | Investigational Site Number 014 | Izumo | Shimane | Japan | |
| 18 | Investigational Site Number 024 | Bunkyō-Ku | Tokyo | Japan | |
| 19 | Investigational Site Number 021 | Chuo Ku | Tokyo | Japan | |
| 20 | Investigational Site Number 009 | Itabashi-ku | Tokyo | Japan | |
| 21 | Investigational Site Number 006 | Minato-Ku | Tokyo | Japan | |
| 22 | Investigational Site Number 004 | Shinagawa-Ku | Tokyo | Japan | |
| 23 | Investigational Site Number 008 | Shinjuku-Ku | Tokyo | Japan | |
| 24 | Investigational Site Number 023 | Shinjuku-Ku | Tokyo | Japan | |
| 25 | Investigational Site Number 012 | Hiroshima | Japan | ||
| 26 | Investigational Site Number 001 | Kumamoto | Japan | ||
| 27 | Investigational Site Number 002 | Kyoto | Japan | ||
| 28 | Investigational Site Number 015 | Nagasaki | Japan | ||
| 29 | Investigational Site Number 016 | Saga | Japan |
Sponsors and Collaborators
- Healios K.K.
Investigators
- Principal Investigator: Kazuya Ichikado, M.D., Ph.D., Saiseikai Kumamoto Hospital
- Principal Investigator: Satoru Hashimoto, M.D., Ph.D., University Hospital, Kyoto Prefectural University of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B04-02